Dr. Abraham investigates a variety of intracellular signaling pathways related to cell-cycle control and cancer development.
Dr. Abraham earned his Ph.D. in Pharmacology from the University of Pittsburgh.
View All Publications
Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.
Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT
Mol Cell Biol. 2002 Oct;22(20):7004-14
Pleiotropic defects in TCR signaling in a Vav-1-null Jurkat T-cell line.
Cao Y, Janssen EM, Duncan AW, Altman A, Billadeau DD, Abraham RT
EMBO J. 2002 Sep 16;21(18):4809-19
ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses.
Bao S, Tibbetts RS, Brumbaugh KM, Fang Y, Richardson DA, Ali A, Chen SM, Abraham RT, Wang XF
Nature. 2001 Jun 21;411(6840):969-74
Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.
Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston D, Elledge SJ, Abraham RT
Genes Dev. 2000 Dec 1;14(23):2989-3002
Pleiotropic contributions of phospholipase C-gamma1 (PLC-gamma1) to T-cell antigen receptor-mediated signaling: reconstitution studies of a PLC-gamma1-deficient Jurkat T-cell line.
Irvin BJ, Williams BL, Nilson AE, Maynor HO, Abraham RT
Mol Cell Biol. 2000 Dec;20(24):9149-61
Robert Abraham's Research Focus
Dr. Abraham investigates a variety of intracellular signaling pathways related to cell-cycle control and cancer development. He has long-standing research interests in the biochemical events that trigger activation, anergy, and apoptosis in antigen-responsive T cells. In separate projects, Dr. Abraham’s group has cloned several members of a novel family of protein kinases, termed PI 3-kinase related kinases (PIKKs). They are intensively investigating the roles of these protein kinases in normal cell functions, including cell growth and signaling through DNA damage-induced cell cycle checkpoints. These research efforts are providing new insights into the pathogenesis of human diseases, particularly cancer, and are leading to the identification of novel targets for anticancer drug discovery.
About Robert Abraham
Robert Abraham earned his Ph.D. in Pharmacology from the University of Pittsburgh in 1981. He trained as a postdoctoral fellow in pharmacology and immunology at the Mayo Clinic and Mayo Foundation in Rochester, Minnesota, where he was promoted to Assistant Professor in 1986 and Associate Professor in 1992. In 1997, Dr. Abraham joined the Department of Pharmacology and Cancer Biology at Duke University Medical Center, where, in 1999, he was appointed Glaxo-Wellcome Professor of Molecular Cancer Biology. Dr. Abraham was recruited to Sanford-Burnham Medical Research Institute in 2001 to found and direct the Institute's Signal Transduction Program. He served as Director of the Institute's NCI-designated Cancer Center from 2002 - 2005, at which time he was recruited to Wyeth Laboratories to direct their cancer drug discovery program. Dr. Abraham maintains collaboration with Sanford-Burnham as an Adjunct Professor.